<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d505" origId="Abarelix"><sentence id="DrugDDI.d505.s0" origId="s0" text="No formal drug/drug interaction studies with Plenaxis? were performed."><entity id="DrugDDI.d505.s0.e0" origId="s0.p0" charOffset="10-14" type="drug" text="drug"/></sentence><sentence id="DrugDDI.d505.s1" origId="s1" text="Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis?."><entity id="DrugDDI.d505.s1.e0" origId="s1.p6" charOffset="0-16" type="drug" text="Cytochrome P-450"/></sentence><sentence id="DrugDDI.d505.s2" origId="s2" text="Plenaxis? is highly bound to plasma proteins (96 to 99%)."><entity id="DrugDDI.d505.s2.e0" origId="s2.p18" charOffset="29-44" type="drug" text="plasma proteins"/></sentence><sentence id="DrugDDI.d505.s3" origId="s3" text="Laboratory Tests Response to Plenaxis? should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter."><entity id="DrugDDI.d505.s3.e0" origId="s3.p30" charOffset="78-96" type="drug" text="total testosterone"/></sentence><sentence id="DrugDDI.d505.s4" origId="s4" text="Serum transaminase levels should be obtained before starting treatment with Plenaxis? and periodically during treatment."><entity id="DrugDDI.d505.s4.e0" origId="s4.p35" charOffset="6-18" type="drug" text="transaminase"/></sentence><sentence id="DrugDDI.d505.s5" origId="s5" text="Periodic measurement of serum PSA levels may also be considered."/></document>